{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:13:23Z","timestamp":1790288003787,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of the gastrointestinal tract (GIT).It results in progressive intestinal epithelium structural and functional damage that necessitates lifetime medication.Thereis imbalance in the production of T helper 1 (Th1), Th2 and Th17 cytokines. This plays a crucial role in the chronic inflammatory process and the defective immune response to pathogenic agents; thus promoting the recurrence of the disease.Our aim of this study was to detect serum IL-17 levels in IBD patients and its relation with disease activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a single center case control study, conducted at hepatology and gastroenterology unit, Mansoura specialized Medical Hospital, Egypt.Patients who were included were aged 18\u201365 years, diagnosed either Ulcerative Colitis (UC)or Crohn\u2019s Disease (CD) based on previous colonoscopy.IBD activity was measured for UC using the MAYO score and CD using the CD activity index (CDAI). Fifty five patients were UC, 24 patients were CD, 21 patients were control.Patients who were excluded were under 15 years old, with history of GIT malignancy, or any serious comorbidities. Study protocol was approved by Institution Research Board (IRB) of Mansoura Medical College.All patients were subjected to full history taking, routine physical examination, colonoscopy and laboratory investigations including serum IL-17 levels by ELISA besides CBC, CRP, ESR and fecal calprotectin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Serum IL-17 level was increased significantly among UC; median (min-max)\u2009=\u200972(21\u2013502)pg\/ml, in CD 54.5(25\u2013260) versus control 19 (14\u201335), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001.However, it was not correlated to the disease activity either Mayo score of UC or CDAI of CD.There was significant correlation to the extent of inflammation in UC affecting the colon (either proctosigmoiditis, left sided colitis or pan colitis), also to the type of CD (either inflammatory, stricturing or fistulizing) by <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05.It was not correlated significantly with any of the IBD activity markers (CRP, ESR, or fecal calprotectin).Yet there was negative significant correlation with Hb level (<jats:italic>r<\/jats:italic> =-0.28, <jats:italic>p<\/jats:italic>\u2009=\u20090.005).There was not significant association between median serum level of IL-17 &amp; duration of disease (<jats:italic>P<\/jats:italic>\u2009=\u20090.6).However, median IL-17 was higher among hospitalized cases than non-hospitalized (73 &amp; 55, pg\/ml respectively; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.002). AUC was significantly differentiating between IBD and control group\u2009=\u20090.993 with the best-detected cut off point from curve 32 pg\/ml yielding sensitivity of 97.5% and specificity of 95.2%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Serum IL-17 increases in colonic inflammation significantly more than in control group, however its increase is not correlated to IBD activity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03218-7","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T12:01:51Z","timestamp":1713182511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Level of interleukin 17 in inflammatory bowel disease and its relation with disease activity"],"prefix":"10.1186","volume":"24","author":[{"given":"Ayman","family":"Menesy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8089-1963","authenticated-orcid":false,"given":"Fatma Adel Mourad","family":"Abozeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"3218_CR1","first-page":"2879","volume":"185","author":"S Federici","year":"2022","unstructured":"Federici S, Sharon, K, R, Rafael VM, Denise K, Akihoko M, et al. Targeted suppression of human IBD - associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. J Gastroenterol. 2022;185:2879\u201395.","journal-title":"J Gastroenterol"},{"key":"3218_CR2","doi-asserted-by":"publisher","first-page":"1055914","DOI":"10.3389\/fimmu.2022.1055914","volume":"9","author":"L Chen","year":"2023","unstructured":"Chen L, Ruan G, Cheng Y, Yi A, Chen D, Wei Y. The role of Th17 cells in inflammatory bowel disease and the research progress. Front Immunol. 2023;9:13:1055914.","journal-title":"Front Immunol"},{"key":"3218_CR3","first-page":"244","volume":"74","author":"L Penso","year":"2022","unstructured":"Penso L, Christina B, Antoine M, Rosemary D, Emilie S, et al. Risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis \/Ankylosing spondylitis initiating Interleukin-17 inhibitors. Am Coll Rheumatol. 2022;74:244\u201352.","journal-title":"Am Coll Rheumatol"},{"key":"3218_CR4","first-page":"2526","volume":"62","author":"S Sarah","year":"2021","unstructured":"Sarah S, Abdul-Hussein EN, Ali, Nawal MF, Alkhalidi, Neihaya H, Zaki, Ali H, Adhiah. Roles of IL-17A and IL-23 in the pathogenesis of Ulcerative Colitis and Crohn\u2019s Disease. Iraqi J Sci. 2021;62:2526\u201335.","journal-title":"Iraqi J Sci"},{"issue":"26","key":"3218_CR5","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317(26):1625\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"3218_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/01.MIB.0000215091.77492.2a","volume":"12","author":"WR Best","year":"2006","unstructured":"Best WR. Predicting the Crohn\u2019s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006;12(4):304\u201310.","journal-title":"Inflamm Bowel Dis"},{"key":"3218_CR7","first-page":"980","volume":"11","author":"A Sahin","year":"2014","unstructured":"Sahin A, Calhan T, Cengiz M, Kahraman R, Aydin K, et al. Serum interleukin 17 levels in patients with Crohn\u2019s disease: real life data. Dis Markers. 2014;11:980.","journal-title":"Dis Markers"},{"key":"3218_CR8","unstructured":"Hulley SB et al. Designing clinical research. LWW, (2013). Goal: estimate an appropriate number of \u2018subjects\u2019 for a given study design."},{"key":"3218_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/cmi.2010.21","volume":"7","author":"S Xu","year":"2010","unstructured":"Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. 2010;7:164\u201374.","journal-title":"Cell Mol Immunol"},{"key":"3218_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5217\/ir.2018.16.1.26","volume":"16","author":"SH Lee","year":"2018","unstructured":"Lee SH, Eun Kwon J, Kim chin H, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intestinal Res. 2018;16:22\u20136.","journal-title":"Intestinal Res"},{"key":"3218_CR11","doi-asserted-by":"crossref","unstructured":"Mahmut Y, Mustafa K, Ihsan A, Hasan K, Ertugrul K. (2016) Are sTWEAK and IL-17A levels in inflammatory bowel Disease Associated with Disease Activity and Etiopathogenesis? Inflammatory bowel disease, 22: 3\u20139.","DOI":"10.1097\/MIB.0000000000000632"},{"key":"3218_CR12","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/jpm11111130","volume":"11","author":"LA Lucaciu","year":"2021","unstructured":"Lucaciu LA, Vesa \u0218C,,Seicean R, Din S, et al. Serum interleukin (IL)-23 and IL-17 profile in inflammatory bowel disease (IBD) patients could differentiate between severe and non-severe disease. J Personalized Med. 2021;11:1130\u201345.","journal-title":"J Personalized Med"},{"key":"3218_CR13","first-page":"5498","volume":"7","author":"JS Feng","year":"2014","unstructured":"Feng JS, Yang Z, Zhu YZ, Liu Z, Guo CC, Zheng XB. Serum IL-17 and IL-6 increased accompany with TGF-\u03b2 and IL-13 respectively in ulcerative colitis patients. Int J Clin Exp Med. 2014;7:5498.","journal-title":"Int J Clin Exp Med"},{"key":"3218_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/MIB.0000000000000632","volume":"22","author":"M Kaplan","year":"2016","unstructured":"Kaplan M, et al. Are sTWEAK and IL-17A levels in inflammatory bowel disease associated with disease activity and etiopathogenesis? Inflamm. Bowel Dis. 2016;22:615\u201322.","journal-title":"Bowel Dis"},{"issue":"1","key":"3218_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","volume":"52","author":"S Fujino","year":"2003","unstructured":"Fujino S, Andoh A, Bamba S, Ogawa A, HataK, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65\u201370.","journal-title":"Gut"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03218-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03218-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03218-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T12:02:48Z","timestamp":1713182568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03218-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3218"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03218-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"29 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects and\/or their legal guardian(s).The Ethical Committee of the Faculty of Medicine of Mansoura University approved the study and the patients to participate. <b>(Code Number: MS.20.10.22)<\/b>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"<b>Not applicable.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Nothing to declare by the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"*All authors have confirmed the manuscript for submission in this journal.*The content of this manuscript has not been published, or submitted for publication elsewhere.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Confirmation"}}],"article-number":"135"}}